India, May 16 -- IQVIA (IQV), a global leader in clinical research and healthcare intelligence, has entered into a strategic collaboration with SCRI Development Innovations, the contract research arm of Sarah Cannon Research Institute.
The partnership aims to revolutionize oncology trials by improving trial operations, speeding up data delivery, and accelerating access to advanced therapies for patients worldwide.
The collaboration combines IQVIA's broad global footprint and its leadership in managing 20% of U.S. oncology trials with SCRI Development Innovations' deep-rooted community oncology expertise. Central to SCRI's contribution is its Accelero operational model, which accelerates trial activation, improves site-level recruitment, a...